Cutting Edge Spine received FDA 510(k) clearance to market the EVOL-SIÂ sacroiliac joint fusion system.
Surface modification on the device is intended to improve osseointegration through hydrophilicity and surface chemistry, while characteristic nano-roughness mediates bioactivity that affects tissue regeneration to yield early bone formation that supports mechanical stability.
Cutting Edge Spine received FDA 510(k) clearance to market the EVOL-SIÂ sacroiliac joint fusion system.
Surface modification on the device is intended to improve osseointegration through hydrophilicity and surface chemistry, while characteristic nano-roughness mediates bioactivity that affects tissue regeneration to yield early bone...
Cutting Edge Spine received FDA 510(k) clearance to market the EVOL-SIÂ sacroiliac joint fusion system.
Surface modification on the device is intended to improve osseointegration through hydrophilicity and surface chemistry, while characteristic nano-roughness mediates bioactivity that affects tissue regeneration to yield early bone formation that supports mechanical stability.
Copy to clipboard 
